Radiopharmaceutical-related pitfalls and artifacts

https://doi.org/10.1016/S0001-2998(96)80002-XGet rights and content

The primary goal of this review article is to increase the reader's knowledge and understanding of problems associated with the radiopharmaceuticals commonly used in daily practice. To achieve this objective, problems related to the commonly used radiopharmaceuticals are divided into pitfalls and artifacts related to radiopharmaceutical preparation (technetium-99m [99mTc]-labeled and non-99mTc-labeled radiopharmaceutical) and those related to radiopharmaceutical administration. For the radiopharmaceutical formulation-associated pitfalls and artifacts, problems are discussed in terms of factor categories, such as factors associated with radionuclides, factors associated with components, factors associated with preparation procedures, and miscellaneous factors. As for the pitfalls and artifacts caused by radiopharmaceutical administration, these problems are categorized into errors associated with administration technique and nontechnical errors. Clinical manifestations (ie, appearance upon imaging) from the numerous literature-based examples are presented. The effects of the causative factors and the reason each factor can result in radiopharmaceutical preparation and administration problems are discussed. In addition, the possible preventive actions are presented for each group. However, the cause of some pharmaceutical related problems may not be easily recognized, and thus it is difficult to develop preventive and/or corrective plans for these cases.

References (465)

  • KimEE et al.

    Unusual or unanticipated alterations in the biodistribution of radiopharmaceuticals as a result of pathologic mechanisms

  • PontoJA et al.

    Clinical manifestations of radiopharmaceutical formulation problems

  • PontoJA

    A review of radiopharmaceutical formulation problems and their clinical manifestations

  • HojelseC et al.

    Factors which affect the integrity of radiopharmaceuticals

  • NeirinckxRD et al.

    Technetium-99m d,l-HM-PAO: A new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion

    J Nucl Med

    (1987)
  • BannisterKM et al.

    Kit preparation of technetium-99m-mercaptoacetyltriglycine: Analysis, biodistribution and comparison with technetium-99m-DTPA in patients with impaired renal function

    J Nucl Med

    (1990)
  • LewisSE et al.
  • LecklitnerML et al.

    Failure of quality control to detect errors in the preparation of technetium-99mdisofenin (DISIDA)

    Clin Nucl Med

    (1985)
  • HuppBD et al.

    Unit dose radiochemical stability of commonly used technetium-99m radiopharmaceuticals

    J Nucl Med Technol

    (1986)
  • TatumJL et al.

    Artifactual focal accumulation of Tc-99m bone imaging tracer in the chest

    Clin Nucl Med

    (1985)
  • HammesRJ et al.

    Quality control of Tc-99m DTPA used for GFR studies

    J Nucl Med

    (1988)
  • RussellCD et al.

    Quality control of technetium-99m DTPA: Correlation of analytic tests with in vivo protein binding in man

    J Nucl Med

    (1986)
  • ShihWJ et al.

    Diffuse thoracoabdominal radioactivity seen in bone imaging

    Clin Nucl Med

    (1986)
  • LamsonML et al.

    Generator-produced 99mTcO4 carrier-free?

    J Nucl Med

    (1975)
  • MolterM

    The current status of 99mTc generators

    Nuklearmedizin

    (1981)
  • AlbersJW et al.

    Free (unreacted) pertechnetate in technetium-sulfur colloid preparations

    J Nucl Med Technol

    (1974)
  • HambrightP et al.

    Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc

    J Nucl Med

    (1975)
  • PorterWV et al.

    The effect of carrier technetium in the preparation of 99mTc-human serum albumin

    J Nucl Med

    (1976)
  • MaughanJ et al.

    Poor binding efficiency using 99Tcm-labeled HSA

    Nucl Med Commun

    (1990)
  • SmithTD et al.

    Chemical effect of 99Tc on 99mTc labeled radiopharmaceuticals

    J Nucl Med

    (1975)
  • SmithTD et al.

    A simple kit for the preparation of 99mTc-labeled red blood cells

    J Nucl Med

    (1976)
  • PorterWC et al.

    Acid-citratedextrose compared with heparin in the preparation of in vivo/in vitro technetium-99m red blood cells

    J Nucl Med

    (1983)
  • WilsonME et al.

    Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit

    J Nucl Med

    (1992)
  • SrivastavaSC et al.

    Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit—Reply

    J Nucl Med

    (1992)
  • WolfangelRG

    Evaluation of heparin and anticoagulant citrate dextrose in the preparation of technetium-99m-red blood cells with UltraTag® RBC kit—Reply

    J Nucl Med

    (1992)
  • KellyMJ et al.

    An assessment of factors which influence the effectiveness of the modified in vivo erythrocyte labeling technique

    J Nucl Med

    (1991)
  • KellyMJ et al.

    An assessment of factors which influence the effectiveness of the modified in vivo technetium-99m-erythrocyte labeling technique in clinical use

    J Nucl Med

    (1992)
  • WolfangelRG et al.

    UltraTag® RBC kit—Relationship between anticoagulants and reagent volume on RBC labeling efficiency and kinetics

    J Nucl Med

    (1992)
  • HungJC et al.

    Optimum concentration of ACD in the preparation of technetium-99m red blood cells with the UltraTag® RBC kit

    J Nucl Med Technol

    (1992)
  • BrandauW et al.

    Determination of brain death with technetium-99m-HMPAO

    J Nucl Med

    (1990)
  • GagnonA et al.

    Labelling efficiency analysis of 99mTc-HMPAO: Comparison between standard elution and multiple elution method

    J Nucl Med

    (1991)
  • PieraC et al.

    Radiochemical purity of technetium-99m-HMPAO depends on specific activity

    J Nucl Med

    (1995)
  • ColombettiLG et al.

    Effect of chemical and radiochemical impurities from eluants on 99mTc-labeling efficiency

    Nuklearmedizin

    (1977)
  • DecristoforoC et al.

    Failure of labeling of anti-granulocyte antibody

    Eur J Nucl Med

    (1993)
  • NoscoDL et al.

    Technetium-99m MAG3: Labeling conditions and quality control

    J Nucl Med Technol

    (1993)
  • HungJC et al.

    Effects of generator eluate age on the radiochemical purity of fractionated 99Tcm-MAG3

    Nucl Med Commun

    (1995)
  • HeroldTJ et al.

    Generator eluate effects on the labeling efficiency of Tc-99m sestamibi kits

    J Nucl Med

    (1993)
  • BallingerJR et al.

    Radiopharmaceutical factors in the variable quality of [99mTc] HMPAO images

    J Nucl Med

    (1990)
  • BayneVJ et al.

    Use of sodium iodide to overcome the eluate age restriction for Ceretec reconstitution

    Nucl Med Commun

    (1989)
  • MillarAM

    A routine method for using sodium iodide to stabilize sodium pertechnetate [99Tcm] dispensed for the preparation of 99Tcm-exametazime

    Nucl Med Commun

    (1992)
  • Cited by (51)

    • Altered Biodistribution of Radiopharmaceuticals: Role of Radiochemical/Pharmaceutical Purity, Physiological, and Pharmacologic Factors

      2010, Seminars in Nuclear Medicine
      Citation Excerpt :

      Even at very low concentrations (1.0 μg/mL), Al3+ reacts with phosphate buffer and forms insoluble aluminum phosphate.27 99mTc-SC coprecipitates with aluminum phosphate and the flocculated particles are trapped in the lung capillaries.3 At higher concentrations (>10 μg/mL), Al3+ may react with 99mTc-MDP forming insoluble particles, which are taken up by the cells of RES in liver (Fig. 2) and spleen.28

    View all citing articles on Scopus
    View full text